Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 9
2020 9
2021 5
2022 6
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Hurvitz SA, et al. Among authors: egorov a. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Lancet. 2023. PMID: 36495879 Free article. Clinical Trial.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. André F, et al. Among authors: egorov a. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. Lancet. 2023. PMID: 37086745 Clinical Trial.
Pixantrone: novel mode of action and clinical readouts.
Minotti G, Han H, Cattan V, Egorov A, Bertoni F. Minotti G, et al. Among authors: egorov a. Expert Rev Hematol. 2018 Jul;11(7):587-596. doi: 10.1080/17474086.2018.1476848. Epub 2018 Jun 18. Expert Rev Hematol. 2018. PMID: 29912583 Review.
Chitosan-Based Antibacterial Films for Biomedical and Food Applications.
Khubiev OM, Egorov AR, Kirichuk AA, Khrustalev VN, Tskhovrebov AG, Kritchenkov AS. Khubiev OM, et al. Among authors: egorov ar. Int J Mol Sci. 2023 Jun 27;24(13):10738. doi: 10.3390/ijms241310738. Int J Mol Sci. 2023. PMID: 37445916 Free PMC article. Review.
Novel Highly Efficient Antibacterial Chitosan-Based Films.
Khubiev OM, Egorov AR, Lobanov NN, Fortalnova EA, Kirichuk AA, Tskhovrebov AG, Kritchenkov AS. Khubiev OM, et al. Among authors: egorov ar. BioTech (Basel). 2023 Jul 7;12(3):50. doi: 10.3390/biotech12030050. BioTech (Basel). 2023. PMID: 37489484 Free PMC article.
DESTINY-Breast03 trial: some questions remain - Authors' reply.
Hurvitz SA, Curigliano G, Egorov A, Ashfaque S, Cortés J. Hurvitz SA, et al. Among authors: egorov a. Lancet. 2023 May 20;401(10389):1653-1654. doi: 10.1016/S0140-6736(23)00681-5. Lancet. 2023. PMID: 37210117 No abstract available.
Perfluorocarbon Nanoemulsions with Fluorous Chlorin-Type Photosensitizers for Antitumor Photodynamic Therapy in Hypoxia.
Nguyen MT, Guseva EV, Ataeva AN, Sigan AL, Shibaeva AV, Dmitrieva MV, Burtsev ID, Volodina YL, Radchenko AS, Egorov AE, Kostyukov AA, Melnikov PV, Chkanikov ND, Kuzmin VA, Shtil AA, Markova AA. Nguyen MT, et al. Among authors: egorov ae. Int J Mol Sci. 2023 Apr 28;24(9):7995. doi: 10.3390/ijms24097995. Int J Mol Sci. 2023. PMID: 37175700 Free PMC article.
39 results